Summary

Overview
Global Chronic Inflammatory Demyelinating Polyneuropathy Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by inflammation of nerve roots and peripheral nerves and destruction of the myelin sheath, which allows nerve fibers to transmit signals rapidly. Damage to myelin can cause slowing or blockage of nerve signals, leading to weakness, paralysis, and motor function impairment, particularly in the arms and legs. Sensory disturbance may also occur. CIDP affects both sides of the body, and the severity and course of the disease may vary from person to person.
Market Dynamics: Drivers & Restraints
Increasing drug approvals by regulatory authorities
Increasing drug approvals by regulatory authorities is expected to boost the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. Newly approved drugs often incorporate the latest advancements in medical research and technology, leading to improved efficacy in managing CIDP symptoms and potentially inducing remission.
For instance, in June 2024, The U.S. Food and Drug Administration approved Vyvgart Hytrulo, a combination of efgartigimod alfa and hyaluronidase-qvfc, for treating chronic inflammatory demyelinating polyneuropathy in adults. It was previously approved for treating adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody positive.
Moreover in December 2023, in December 2023, Takeda announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of HYQVIA as maintenance therapy in patients with CIDP after stabilization with IVIG.

Side effects associated with CIDP

Around 54% of CIDP cases are misdiagnosed, leading to minimal to no benefit from long-term immunosuppressive therapy. Despite available treatments, most patients with CIDP have some form of disability and may suffer from side effects like hypertension, infection, bone marrow suppression, nephrotoxicity, and malignancies.
Complications include aspiration pneumonia, atelectasis, respiratory failure, and autonomic function involvement, causing gastrointestinal motility abnormalities, bladder function, orthostatic hypotension, and cardiac conduction defects.
For more details on this report – Request for Sample
Segment Analysis
The global chronic inflammatory demyelinating polyneuropathy market is segmented based on treatment type, route of administration, end-user, and region.
The immunoglobulin therapy from the treatment type segment accounted for approximately 42.3% of the chronic inflammatory demyelinating polyneuropathy market share
The immunoglobulin therapy from the treatment type segment accounted for approximately 42.3%. IVIG, or intravenous immune globulin, is a therapy for chronic inflammatory demyelinating polyneuropathy, derived from donated human plasma antibodies that block immune and inflammatory processes that damage myelin.
For instance, in January 2024, Takeda received FDA approval for GAMMAGARD LIQUID, an intravenous immunoglobulin therapy, to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The therapy can be used as an induction and maintenance dose but has not been studied in immunoglobulin-naive patients or as maintenance therapy for longer than six months.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors such as novel drug launches, FDA approvals, initiatives from governments and other organizations that are expected to influence the global chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market growth.
For instance, in May 2024, Zai Lab Limited received a supplemental Biologics License Application (sBLA) from the China National Medical Products Administration (NMPA) for efgartigimod alfa injection (efgartigimod SC) for treating chronic inflammatory demyelinating polyneuropathy (CIDP).
Market Segmentation
By Treatment Type
• Immunoglobulin Therapy
o Intravenous Immunoglobulin (IVIG)
o Subcutaneous Immunoglobulin (SCIG)
• Corticosteroids
o Oral Corticosteroids
o Injectable Corticosteroids
o Plasma Exchange (Plasmapheresis)
o Others
• Immunosuppressants
• Physical Therapy
• Plasma Exchange
By Route of Administration
• Oral
• Intravenous
• Others
By End User
• Hospitals
• Specialty Clinics
• Research and Academic Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Bio Products Laboratory Ltd, Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation,CSL Behring, Teijin Pharma Limited, Pfizer, Inc among others.
Key Developments
 In July 2023, Argenx SE, a global immunology company, announced positive results from the ADHERE study evaluating VYVGART Hytrulo in adults with chronic inflammatory demyelinating polyneuropathy. The study met its primary endpoint, demonstrating a significantly lower risk of relapse with VYVGART Hytrulo compared to the placebo. The detailed data will be presented at an upcoming medical meeting.

Why Purchase the Report?
• To visualize the global chronic inflammatory demyelinating polyneuropathy market segmentation based on treatment type, route of administration, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the chronic inflammatory demyelinating polyneuropathy market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global chronic inflammatory demyelinating polyneuropathy market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing drug approvals by regulatory authorities
4.1.1.2. Rise in the prevalence of Chronic Inflammatory Demyelinating Polyneuropathy
4.1.2. Restraints
4.1.2.1. Side effects associated with CIDP
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Treatment Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Immunoglobulin Therapy *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Corticosteroids
6.4. Immunosuppressants
6.5. Physical Therapy
6.6. Plasma Exchange
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Intravenous
7.4. Others
8. By End User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Speciality Clinics
8.4. Research and Academic Institutes
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Bio Products Laboratory Ltd*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Momenta Pharmaceuticals
11.3. Grifols
11.4. Baxter
11.5. Kedrion S.p.A
11.6. Octapharma
11.7. Mitsubishi Tanabe Pharma Corporation
11.8. CSL Behring
11.9. Teijin Pharma Limited
11.10. Pfizer, Inc

LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us